Clinical trial NCT05003154: Digitalized Management Exploration for Gestational Diabetes Mellitus in China
Official title: Comparison of Conventional Mode and Combined Digitalized Mode of Management for Gestational Diabetes Mellitus in China
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Gestational Diabetes Mellitus in Pregnancy
Lead sponsor: Women's Hospital School Of Medicine Zhejiang University
Sponsor class: OTHER
Collaborators: name: Hangzhou Jianhai Technology Company Limited
name: Quzhou Maternal and Child Health Care Hospital
First posted: 2021-08-12
Enrollment: 46
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Gestational diabetes mellitus (GDM) can lead to adverse perinatal and long-term outcomes, and it is so important to manage this disease in pregnancy. Digitalized managements have been proved economical and effective in some chronic diseases like type II diabetes mellitus. The purpose of the current study was to develop and evaluate a digitalized mode for GDM management using mobile healthcare and some wearable devices. Subjects were randomly divided into a conventional management group and combined digitalized management group after diagnosed with GDM during 24-28 weeks of gestation. The conventional mangement group received conventional GDM management and could freely use the mobile healthcare application. The mobile management group received digitalized healthcare services from artificial intelligence under the supervision of obstetricians, in addition to conventional management. The effectiveness of digitalized management were evaluated mainly through the result values of the labotatory tests related to blood glucose controlling and perinatal outcomes.


Eligibility criteria: Inclusion Criteria:

1. The age of 18-45 years, single pregnancy, Han nationality;
2. GDM diagnosed between 24 to 28 weeks of gestation, either of the following: fasting plasma glucose ≥5.1 mmol/L, 60-minute plasma glucose ≥10.0 mmol/L, 120-minute plasma glucose ≥8.5 mmol/L, during a 75g oral glucose tolerance test (OGTT).
3. Plan to deliver the baby in Women's Hospital School Of Medicine Zhejiang University;
4. Can operate mobile phones and related software;
5. Voluntary participation in this study;
6. Education background: junior high school or above.

Exclusion Criteria:

1. Type I or II or other non GDM diabetes mellitus;
2. Severe pregnancy complications or complications: such as malignant tumor, preeclampsia, severe intrahepatic cholestasis of pregnancy syndrome, pregnancy with antiphospholipid antibody syndrome, severe anemia (hemoglobin\<90g/L, etc.), cardiac insufficiency cardiovascular disease (such as myocardial infarction, heart failure, pulmonary hypertension, stroke history, coronary heart disease, valvular heart disease, etc.), stroke (moderate), liver disease (such as hepatic insufficiency, acute viral hepatitis, etc.), lung disease (such as restrictive lung disease, emphysema, liver cirrhosis, pulmonary heart disease, etc.), kidney disease (such as nephrotic syndrome, chronic nephritis, renal insufficiency, etc.), chronic hypertension, thyroid disease (such as hyperthyroidism, hypothyroidism, thyroiditis, etc.), other endocrine diseases (such as Cushing's syndrome Acromegaly, venous or arterial thromboembolic diseases, rheumatic immune diseases, etc;
3. The combined conditions that may affect the diet exercise therapy include severe food allergy, dyskinesia (physical disability), history of bariatric surgery, major gastrointestinal diseases (such as gastrointestinal bleeding, inflammatory bowel disease, gastrointestinal tumor, active stage of peptic ulcer, chronic intestinal obstruction, etc.), restrictive lung disease, history of two or more adverse abortions, placenta previa, repeated and persistent bleeding threatened abortion, threatened premature birth, hyperemesis gravidarum, vegetarians, etc;
4. Other conditions: such as mental disorders, cervical incompetence, genital tract deformity, etc;
5. Patients who are taking medicine that may affect glucose metabolism, such as ritodrine, prednisone, etc;
6. Patients who are participating in other clinical studies;
7. The researchers believe patients who are not suitable for this study

Primary outcomes:
measure: Concentration of glycosylated hemoglobin A1c
timeFrame: 37-42 weeks of gestation
Secondary outcomes:
measure: Rate of neonate large for gestational age
timeFrame: At the 1 day of delivery
measure: rate of caesarean as the delivery mode
timeFrame: At the 1 day of delivery
measure: Hospitalization cost of neonate and puerperae for delivery
timeFrame: At the 1 day discharging from hospital
measure: Proportion of patients with abnormal resulets of postnatal oral glucose tolerance test
timeFrame: 42 days postpartum
Other outcomes:
Locations:
city: HangZhou
country: China
facility: Danqing Chen
state: Zhejiang
Study officials:
References: